Complement C9 (C9) Mouse Monoclonal Antibody [Clone ID: aE11]

Specifications

Product Data
Clone Name	aE11
Applications	ELISA, FN, IF, IHC
Recommend Dilution	Immunohistochemistry on Frozen Sections (Ref.6): The typical starting working dilution is 1/50. Immunohistochemistry on Paraffin Sections (Ref.4): The typical starting working dilution is 1/50. Flow Cytometry (Ref.5): The typical starting working dilution is 1/50. Functional Studies (Ref.3,5): Inhibits platelet activation by antiphospholipid antibody serum (Ref.5). Immunoassays (Ref.1,2). Immunofluorescence (Ref.2,4). Positive Control: Mucosa from patients with H. Pylori.
Reactivity	Equine, Human, Porcine
Host	Mouse
Clonality	Monoclonal
Specificity	This antibody reacts with a C9 neoantigen of the terminal complement complex (TCC).
Formulation	PBS State: Purified State: Liquid 0.2 µm filtered Ig fraction Stabilizer: 0.1% BSA
Concentration	lot specific
Purification	Protein G Chromatography
Conjugation	Unconjugated
Storage Condition	Store undiluted at 2-8°C.
Gene Name	complement component 9
Database Link	Entrez Gene 735 Human UniProt ID P02748
Background	The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.
Synonyms	Complement component C9, Complement 9
Reference Data

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.